A new systematic review and meta-analysis showed a small but significant reduction in subjective pain scores for cannabinoid treatment compared to placebo in patients experiencing acute pain. No increase in serious adverse events suggested the safety of using cannabinoids to treat acute pain, according to the study published in Cannabis
Free Webinar: The Endocannabinoid System: Therapeutic Impact of Hemp and Full-spectrum Cannabinoids.
Healthcare professionals often have a knowledge gap when it comes to navigating the nascent hemp industry and providing evidence-based counseling to their communities. This webinar, Endocannabinoid System: Therapeutic Impact of Hemp and Full-spectrum Cannabinoids with Alex Capano, PhD, NP, BSN, MSN will cover the therapeutic potential and current scientific evidence
In November 2019 FDA issued a strong set of warning statements about cannabidiol. The agency said that “based on the lack of scientific information supporting the safety of CBD in food, the FDA … cannot conclude that CBD is generally recognized as safe (GRAS) among qualified experts for its use
A new study shows that cannabis may be helpful to address the effects of post-traumatic stress disorder (PTSD). According to health survey data collected by Statistics Canada from more than 24,000 Canadians, researchers from the BC Centre on Substance Use (BCCSU) and University of British Columbia (UBC) found that people
In this summary-scientific review from Mayo Clinical Proceedings, the researchers provide an overview of the scientific work on cannabidiol and hemp oil and the distinction between marijuana, hemp, and the different components of CBD and hemp oil products. They summarize the current legal status of CBD and hemp oils in
Do you have questions about the therapeutic applications of CBD? We thought so. Preclinical and clinical studies suggest that cannabidiol (CBD) has broad therapeutic value. With emerging knowledge and a lack of education about the Endocannabinoid System (ECS) in most medical schools, the vast majority of health professionals have limited
The FDA announced that it will host further cannabidiol hearing on the regulatory structure of CBD products in the early fall. The news was embedded in a press release regarding a warning issued to a CBD maker CuraLeaf for making unfounded claims to treat cancer, Alzheimer’s disease, opioid withdrawal, pain